IL-35 is a novel responsive anti-inflammatory cytokine - a new system of categorizing anti-inflammatory cytokines

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Li, Xinyuan ^a   Mai, Jietang ^a   Virtue, Anthony ^a   Yin, Ying ^a   Gong, Ren ^a   Sha, Xiaojin ^a   Gutchigian, Stefanie ^a   Frisch, Andrew ^a   Hodge, Imani ^a   Jiang, Xiaohua ^a   Wang, Hong ^a   Yang, Xiao Feng ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 27; INTERLEUKIN 35; MICRORNA; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE; INTERLEUKIN 35, HUMAN; INTERLEUKIN 35, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN; INTERLEUKIN-35, MOUSE; MESSENGER RNA;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DATA MINING; EBI3 GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HEART; HUMAN; HUMAN TISSUE; IL10 GENE; IL12A GENE; IL35 GENE; KIDNEY; LIVER; LUNG; MARKER GENE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; SPLEEN; STATISTICAL ANALYSIS; STRUCTURE ANALYSIS; TGBF3; TGFB1 GENE; TGFB2 GENE; THYMUS; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION; ALTERNATIVE RNA SPLICING; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CHEMISTRY; CLASSIFICATION; DNA METHYLATION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN SUBUNIT; REGULATORY T LYMPHOCYTE;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; CYTOKINES; DNA METHYLATION; GENE EXPRESSION; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; INTERLEUKINS; MICE; MICE, KNOCKOUT; MICRORNAS; MODELS, IMMUNOLOGICAL; PROMOTER REGIONS, GENETIC; PROTEIN SUBUNITS; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84863376362     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033628     Document Type: Article

References (67)

1. Medzhitov R, Shevach EM, Trinchieri G, Mellor AL, Munn DH, et al. (2011) Highlights of 10 years of immunology in Nature Reviews Immunology. Nat Rev Immunol 11: 693-702.
2. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, et al. (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12: 178-180.
3. Xiong Z, Song J, Yan Y, Huang Y, Cowan A, et al. (2008) Higher expression of Bax in regulatory T cells increases vascular inflammation. Front Biosci 13: 7143-7155.
4. Xiong Z, Yan Y, Song J, Fang P, Yin Y, et al. (2009) Expression of TCTP antisense in CD25(high) regulatory T cells aggravates cuff-injured vascular inflammation. Atherosclerosis 203: 401-408.
5. Mai J, Wang H, Yang XF, (2010) Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity. Front Biosci 15: 986-1006.
6. O'Shea JJ, Ma A, Lipsky P, (2002) Cytokines and autoimmunity. Nat Rev Immunol 2: 37-45.
7. Dinarello CA, (2009) Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 360: 2467-2470.
8. Boraschi D, Dinarello CA, (2006) IL-18 in autoimmunity: review. Eur Cytokine Netw 17: 224-252.
9. Bettini M, Vignali DA, (2009) Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 21: 612-618.
10. Salmaggi A, Dufour A, Eoli M, Corsini E, La Mantia L, et al. (1996) Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression? J Neurol 243: 13-17.
11. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H, (2003) Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 91: 133-136.
12. Narverud I, Ueland T, Nenseter MS, Retterstol K, Telle-Hansen VH, et al. (2011) Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor alpha system and interleukin-10. Atherosclerosis 214: 163-168.
13. Cua DJ, Groux H, Hinton DR, Stohlman SA, Coffman RL, (1999) Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J Exp Med 189: 1005-1010.
14. Cua DJ, Hutchins B, LaFace DM, Stohlman SA, Coffman RL, (2001) Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol 166: 602-608.
15. Collison LW, Vignali DA, (2008) Interleukin-35: odd one out or part of the family? Immunol Rev 226: 248-262.
16. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, et al. (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566-569.
17. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA, (2011) Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 186: 6661-6666.
18. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L'Hermine A, Devergne O, (2008) Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 181: 6898-6905.
19. Tedgui A, Mallat Z, (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86: 515-581.
20. Chen NC, Yang F, Capecci LM, Gu Z, Schafer AI, et al. (2010) Regulation of homocysteine metabolism and methylation in human and mouse tissues. Faseb J 24: 2804-2817.
21. Yin Y, Yan Y, Jiang X, Mai J, Chen NC, et al. (2009) Inflammasomes are differentially expressed in cardiovascular and other tissues. Int J Immunopathol Pharmacol 22: 311-322.
22. Ueland PM, Helland S, Broch OJ, Schanche JS, (1984) Homocysteine in tissues of the mouse and rat. J Biol Chem 259: 2360-2364.
23. Virtue A, Mai J, Yin Y, Meng S, Tran T, et al. (2011) Structural evidence of anti-atherogenic microRNAs. Front Biosci 17: 3133-3145.
24. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, et al. (2012) The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol.
25. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, et al. (2010) Biology of interleukin-10. Cytokine Growth Factor Rev 21: 331-344.
26. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, et al. (2003) Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 9: 10-17.
27. Bobik A, (2006) Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 26: 1712-1720.
28. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, et al. (2010) IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11: 1093-1101.
29. Homma Y, Cao S, Shi X, Ma X, (2007) The Th2 transcription factor c-Maf inhibits IL-12p35 gene expression in activated macrophages by targeting NF-kappaB nuclear translocation. J Interferon Cytokine Res 27: 799-808.
30. Poleganov MA, Bachmann M, Pfeilschifter J, Muhl H, (2008) Genome-wide analysis displays marked induction of EBI3/IL-27B in IL-18-activated AML-derived KG1 cells: critical role of two kappaB binding sites in the human EBI3 promotor. Mol Immunol 45: 2869-2880.
31. Sahoo A, Im SH, (2010) Interleukin and interleukin receptor diversity: role of alternative splicing. Int Rev Immunol 29: 77-109.
32. Davuluri RV, Suzuki Y, Sugano S, Plass C, Huang TH, (2008) The functional consequences of alternative promoter use in mammalian genomes. Trends Genet 24: 167-177.
33. Thierry-Mieg D, Thierry-Mieg J, (2006) AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol 7 (Suppl 1): S12 11-14.
34. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, et al. (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16: 779-790.
35. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, et al. (1996) A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 70: 1143-1153.
36. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, et al. (2005) Towards a proteome-scale map of the human protein-protein interaction network. Nature 437: 1173-1178.
37. Kim Y, Sung JY, Ceglia I, Lee KW, Ahn JH, et al. (2006) Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature 442: 814-817.
38. Kubin M, Kamoun M, Trinchieri G, (1994) Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 180: 211-222.
39. Yang Y, Yang F, Xiong Z, Yan Y, Wang X, et al. (2005) An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene 24: 4778-4788.
40. MacDonald SM, Rafnar T, Langdon J, Lichtenstein LM, (1995) Molecular identification of an IgE-dependent histamine-releasing factor. Science 269: 688-690.
41. Wilson CB, Rowell E, Sekimata M, (2009) Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 9: 91-105.
42. Jamaluddin MS, Yang X, Wang H, (2007) Hyperhomocysteinemia, DNA methylation and vascular disease. Clin Chem Lab Med 45: 1660-1666.
43. James SJ, Melnyk S, Pogribna M, Pogribny IP, Caudill MA, (2002) Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 132: 2361S-2366S.
44. Caudill MA, Wang JC, Melnyk S, Pogribny IP, Jernigan S, et al. (2001) Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine beta-synthase heterozygous mice. J Nutr 131: 2811-2818.
45. Li J, Bardag-Gorce F, Oliva J, Dedes J, French BA, et al. (2009) Gene expression modifications in the liver caused by binge drinking and S-adenosylmethionine feeding. The role of epigenetic changes. Genes Nutr.
46. Ordovas JM, Smith CE, (2010) Epigenetics and cardiovascular disease. Nat Rev Cardiol 7: 510-519.
47. Ikushima H, Miyazono K, (2011) TGF-beta signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-beta. Cell Tissue Res.
48. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, et al. (2005) Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 26: 1856-1867.
49. Szyf M, (2010) Epigenetic therapeutics in autoimmune disease. Clin Rev Allergy Immunol 39: 62-77.
50. Bakheet T, Williams BR, Khabar KS, (2006) ARED 3.0: the large and diverse AU-rich transcriptome. Nucleic Acids Res 34: D111-114.
51. Jalonen U, Nieminen R, Vuolteenaho K, Kankaanranta H, Moilanen E, (2006) Down-regulation of tristetraprolin expression results in enhanced IL-12 and MIP-2 production and reduced MIP-3alpha synthesis in activated macrophages. Mediators Inflamm 2006: 40691.
52. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
53. Zhang C, (2008) MicroRNAs: role in cardiovascular biology and disease. Clin Sci (Lond) 114: 699-706.
54. Rasmussen KD, Simmini S, Abreu-Goodger C, Bartonicek N, Di Giacomo M, et al. (2010) The miR-144/451 locus is required for erythroid homeostasis. J Exp Med 207: 1351-1358.
55. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, et al. (2009) miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460: 705-710.
56. Naeem H, Kuffner R, Csaba G, Zimmer R, (2010) miRSel: automated extraction of associations between microRNAs and genes from the biomedical literature. BMC Bioinformatics 11: 135.
57. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, et al. (2005) Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120: 623-634.
58. Sethupathy P, Corda B, Hatzigeorgiou AG, (2006) TarBase: A comprehensive database of experimentally supported animal microRNA targets. Rna 12: 192-197.
59. Asirvatham AJ, Magner WJ, Tomasi TB, (2009) miRNA regulation of cytokine genes. Cytokine 45: 58-69.
60. Devergne O, Birkenbach M, Kieff E, (1997) Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A 94: 12041-12046.
61. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, et al. (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37: 3021-3029.
62. Wirtz S, Billmeier U, McHedlidze T, Blumberg RS, Neurath MF, (2011) Interleukin-35 Mediates Mucosal Immune Responses that Protect Against T-Cell-Dependent Colitis. Gastroenterology.
63. Zandian M, Mott KR, Allen SJ, Dumitrascu O, Kuo JZ, et al. (2011) Use of cytokine immunotherapy to block CNS demyelination induced by a recombinant HSV-1 expressing IL-2. Gene Ther.
64. Huang CH, Loo EX, Kuo IC, Soh GH, Goh DL, et al. (2011) Airway Inflammation and IgE Production Induced by Dust Mite Allergen-Specific Memory/Effector Th2 Cell Line Can Be Effectively Attenuated by IL-35. J Immunol 187: 462-471.
65. Holloway DT, Kon M, DeLisi C, (2005) Integrating genomic data to predict transcription factor binding. Genome Inform 16: 83-94.
66. Zill P, Engel R, Baghai TC, Juckel G, Frodl T, et al. (2002) Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression. Neuropsychopharmacology 26: 489-493.
67. Chiu IM, Touhalisky K, Baran C, (2001) Multiple controlling mechanisms of FGF1 gene expression through multiple tissue-specific promoters. Prog Nucleic Acid Res Mol Biol 70: 155-174.